CROSS-RECORD REVIEW / FOUR COMPOUNDS
Compare the Evidence, Not Just the Names
A structured view of what can be grouped, what must stay separate, and where each compound’s evidence is mature or limited.
In plain English
These four compounds do not compete for one job. CJC-1295 and tesamorelin both signal through the growth-hormone-releasing hormone receptor, but they are different molecules with different durations, clinical histories, and regulatory positions. Semaglutide acts through the GLP-1 receptor and has large metabolic-outcome trials. PT-141 is bremelanotide and acts in central melanocortin pathways related to sexual desire.
The useful comparison begins with identity. CJC-1295 DAC should not be merged with the short-acting no-DAC form. PT-141 and bremelanotide should be linked as a code and nonproprietary name for the same compound. Semaglutide product names can be reconciled to one active molecule while preserving formulation and indication. Tesamorelin findings should retain their HIV-lipodystrophy population. After that work, evidence maturity becomes clearer: early pharmacology for CJC-1295, large outcome programs for semaglutide, focused randomized trials for tesamorelin, and indication-specific phase 3 evidence for bremelanotide. This is a map of unlike records, not a treatment ranking.
The comparison matrix
| Record | Identity rule | Primary pathway | Best-supported research context | Evidence maturity |
|---|---|---|---|---|
| CJC-1295 | Separate DAC from no-DAC / Modified GRF (1-29) | GHRH receptor → GH/IGF-1 | Hormone pharmacology in small early human studies | Investigational; no approved human indication [1][4][5] |
| Semaglutide | Unify codes and product names at molecule level; retain route and indication | GLP-1 receptor | Weight, cardiovascular, kidney, and diabetes-related outcomes in defined populations | Large randomized outcome programs and approved uses [9][10][11] |
| Tesamorelin | Unify TH9507 and tesamorelin; retain HIV-lipodystrophy population | GHRH receptor → GH/IGF-1 | Visceral-fat reduction in adults with HIV-associated lipodystrophy | Approved narrow indication with randomized trials [13][14][15][17] |
| PT-141 / bremelanotide | Unify research code and nonproprietary name; distinguish regulated product from unverified material | Central MC4R/MC3R signaling | Acquired, generalized HSDD in premenopausal women | Phase 3 and label evidence for a defined indication [19][20][21][22] |
Where names should merge
A development code and a later nonproprietary name often describe one molecule at different stages of its record. PT-141 and bremelanotide are the clearest example here. Counting a PT-141 mechanism paper and a bremelanotide trial as evidence for two separate compounds would create a false sense of replication. Semaglutide’s development codes and product names also connect to one active molecule. The correct unit of synthesis is the active compound, annotated with formulation, population, route, and indication.
Tesamorelin and TH9507 likewise belong to one record. Combining those names improves recall during literature search. It does not erase study context: the central efficacy record remains focused on HIV-associated lipodystrophy [13][15][17]. Name reconciliation should make the evidence more complete, never broader than the source supports.
Where names should split
CJC-1295 shows why aggressive deduplication can be as misleading as none at all. The DAC form contains the albumin-binding design responsible for prolonged exposure, while the no-DAC form lacks it [7]. Informal sources often use “CJC-1295” for both. A synthesis should therefore split records by form when exposure or safety interpretation depends on duration, even if both descend from the same modified hGRF(1-29) scaffold.
Product and supply distinctions also matter. An approved product and an unregulated preparation bearing the same molecule name are not equivalent evidence objects. Analytical identification of CJC-1295 in a seized preparation illustrates why the printed label cannot substitute for verified composition [2]. Identity reconciliation is a scientific mapping exercise, not product authentication.
Mechanism is not an outcome
CJC-1295 and tesamorelin can be grouped for discussion of GHRH-receptor signaling, yet their outcome evidence should remain separate. CJC-1295 studies establish prolonged hormone responses and preserved pulsatility [4][5]. Tesamorelin trials measure visceral and hepatic fat in a defined clinical population [13][15][17]. A shared receptor does not transfer the latter findings to the former compound.
The same rule separates semaglutide and PT-141 from the GHRH pair. Semaglutide’s GLP-1 pharmacology connects appetite, glucose regulation, cardiovascular outcomes, and kidney outcomes, but each claim still belongs to its trial population [9][10][11]. Bremelanotide’s central melanocortin mechanism is supported by neuroimaging and clinical trials focused on desire and distress [19][20]. Mechanistic grouping helps explain; it does not authorize pooled efficacy.
A practical evidence hierarchy
For this collection, evidence maturity is best read as a set of lanes. Large randomized outcome trials give semaglutide the broadest clinical program, but not universal applicability. Tesamorelin has focused randomized and longer-term evidence for one approved context. Bremelanotide has phase 3 and extension evidence tied to a specific diagnosis and population. CJC-1295 has informative early pharmacology and preclinical work without an approved clinical endpoint.
Community reports sit outside those lanes. Where included on compound pages, they are labeled anecdotal, not clinical evidence. They can reveal recurring questions or tolerability themes, but they do not upgrade an investigational compound, expand an approved indication, or yield a comparative effect size. The disciplined conclusion is not that one peptide is “best.” It is that each evidence record answers a different question, with a different level of certainty.